Where can I listen to this podcast?

This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

Yes, this podcast regularly features guests.

Precision Pathology Podcast (P³)

Claim This Podcast

by Perelman School of Medicine, Pathology & Laboratory Medicine

5.0(3 reviews)

10 episodes

Updated Daily

Accepts GuestsHas SponsorsLocation 🇺🇸

Podcast Overview

Precision Pathology Podcast (P³) features monthly interviews hosted by George J. Netto, MD, Chair of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine. In each episode, he engages with global thought leaders and authors who are at the forefront of cutting- edge research in pathology and biomedical science. The discussions are easy to follow and highly informative, covering a wide range of groundbreaking technological advancements in precision diagnostics and therapeutics. Topics include digital and computational pathology, single-cell and spatial omics, as well as multiplex biomarker assessment, which are transforming diagnostics, targeted therapies, immunotherapy, and cellular therapeutics.

Language

🇺🇲

Publishing Since

8/27/2025

Visit Website View on Apple Podcasts RSS Feed

1 verified contact email on file for Precision Pathology Podcast (P³)

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

See contact details

Recent Episodes

July 17, 2026

How CAR T-Cell Therapy Enabled Kidney Transplants for Highly Sensitized Patients

<a href="https://support.doctorpodcasting.com/media/k2/items/cache/d608df60481bff88c1b197900ebb0593_Generic.jpg"><img align="right" border="0" src="https://support.doctorpodcasting.com/media/k2/items/cache/d608df60481bff88c1b197900ebb0593_S.jpg" alt="how-car-t-cell-therapy-enabled-kidney-transplants-for-highly-sensitized-patients" /></a>This episode explains how a novel CAR T-cell approach made kidney transplantation possible for patients previously considered unmatched, and why that could change outcomes for people waiting on dialysis. Dr. Vijay Bhoj, MD, PhD, assistant professor of pathology and cellular immunotherapy at the University of Pennsylvania, walks through the phase 1, multi-institutional trial that combined CD19 and BCMA CAR T-cells to achieve durable antibody reduction and successful transplants. Listen to the Podcast and watch the full vodcast on our YouTube channel for details. Keywords: CAR T-Cell therapy, kidney transplantation, BCMA, CD19, plasmapheresis.

June 16, 2026

Leveraging the Million Veteran Program Dataset to Bring a Prostate Genomic Risk to the Clinic: the ProGRESS study

<a href="https://support.doctorpodcasting.com/media/k2/items/cache/5d6fb90d22613c92f1cd032e4d033bb7_Generic.jpg"><img align="right" border="0" src="https://support.doctorpodcasting.com/media/k2/items/cache/5d6fb90d22613c92f1cd032e4d033bb7_S.jpg" alt="leveraging-the-million-veteran-program-dataset-to-bring-a-prostate-genomic-risk-to-the-clinic-the-progress-study" /></a>In this episode, we discuss the recent publication in Nature Cancer by Jason L. Vassy et al. on building a personalized genomic risk model to enhance precision in prostate cancer screening. Guest Kara Maxwell, MD, PhD, from the University of Pennsylvania, explains how the PCARE test combines a polygenic risk score with genetic ancestry and family history to guide PSA decisions in clinical care. You'll hear how the Million Veteran Program enabled model development, why monogenic mutations were added to the clinical assay, and what the randomized PROGRESS trial will test about PSA screening pathways.

May 27, 2026

GLP-1 Receptor Agonists and Cancer Risk Reduction: What is the Verdict?

<a href="https://support.doctorpodcasting.com/media/k2/items/cache/619df471089fd3e072f32e477d4299e8_Generic.jpg"><img align="right" border="0" src="https://support.doctorpodcasting.com/media/k2/items/cache/619df471089fd3e072f32e477d4299e8_S.jpg" alt="glp-1-receptor-agonists-and-cancer-risk-reduction-what-is-the-verdict" /></a>Glucagon-like peptide 1 receptor agonists (GLP1RAs) are widely used to treat type 2 diabetes mellitus (T2DM) and obesity. Given that T2DM and obesity are associated with a higher risk of cancer, the potential of GLP1RAs use to reduce cancer risk is of great interest. Professor Edoardo Mannucci from the University of Florence, Italy, discusses his recent publication in Nature Reviews Clinical Oncology (March 2026) on the current evidence from preclinical and clinical studies on the heterogeneous effects of GLP1RAs on cancer risk. The incidence of hepatocellular, oesophageal, endometrial, ovarian, and prostate cancers might be reduced, whereas safety concerns remain with respect to thyroid (both medullary and non-medullary) carcinoma. #GLP1 #Weight Loss #Obesity #Diabetes #Cancer Risk

10 total episodes available

Deep-dive analytics for Precision Pathology Podcast (P³)

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is Precision Pathology Podcast (P³)?: Precision Pathology Podcast (P³) features monthly interviews hosted by George J. Netto, MD, Chair of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine. In each episode, he engages with global thought leaders and authors who are at the forefront of cutting- edge research in pathology and biomedical science.

The discussions are easy to follow and highly informative, covering a wide range of groundbreaking technological advancements in precision diagnostics and therapeutics. Topics include digital and computational pathology, single-cell and spatial omics, as well as multiplex biomarker assessment, which are transforming diagnostics, targeted therapies, immunotherapy, and cellular therapeutics.
How often does this podcast release new episodes?: This podcast updates daily.
Where can I listen to this podcast?: This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Does this podcast accept guests?: Yes, this podcast regularly features guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.